In "Recognizing EPP: Diagnostic Red Flags, Psychosocial Burden, and Confirmatory Workup," Dr. Bonkovsky turns to what should ...
Galderma announced an agreement to acquire ZO Skin Health for an enterprise value of $1.5 billion, a move designed to expand ...
Dr. Singh stresses that tolerability is key to achieving good outcomes with hedgehog inhibitors. Baseline and periodic ...
Sitryx Therapeutics announced positive topline results from a Phase 1b trial of SYX-5219, a first-in-class oral pyruvate ...
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about ...
Adults with chronic hand eczema (CHE) treated within the Duke University Health System reported substantial work productivity ...
In "Case 2: Escalating Therapy After Biologic Failure in HS," the panel shifts to the series' second patient case.
Cosibelimab (Unloxcyt; Sun Pharma), a PD-L1 inhibitor, is also approved for locally advanced and metastatic cutaneous ...
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in ...
A patient with 45 percent hair loss and a wedding in six months illustrates why psychosocial burden can reclassify disease ...
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline. From viral skin care hacks to trendy treatment devices, social ...
The DecisionDx-Melanoma 31-GEP test recently released top data from the largest prospective GEP study. The study was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results